RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data across multiple hematologic malignancies will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla. from Dec. 6-9. The data shared at the meeting will highlight the company's ongoing commitment to advancing clinical research in hematology across Merck's expanding and diverse pipeline of investigational candidates ...

智通财经APP获悉，默沙东(MRK.US)已建议其股东拒绝Tutanota主动提出的"迷你股权"收购要约，并指 出接受该要约的股东可能最终会以低于当前默沙东股价的价格出售其股份。 这家总部位于新泽西州的制药巨头表示，Tutanota于11月10日提出以每股65.00美元的价格收购至多100 万股默沙东普通股，该价格较11月7日(收购要约发出前最后一个交易日)的默沙东股票收盘价低近25%。 默沙东在上周五晚些时候的新闻稿中指出，该出价也较11月20日该公司股票的收盘价低约32%。该公司 声明与此项收购要约无关，且该要约涉及的股份低于默沙东流通股的5%门槛，从而规避了监管审查。 默沙东补充表示不认可此要约，并称："与Tutanota的其他收购要约一样，此次要约使个人投资者面临风 险，因为他们可能没有意识到自己正在折价出售股份。"因此，该公司建议股东拒绝此要约，并告知已 接受要约的股东在12月15日截止日期前撤回。 ...

Core Insights - The discussion emphasizes a "barbell approach" to investing during periods of market volatility, focusing on both high dividend income stocks and AI growth stocks to balance risk and return [9][10][41]. Investment Strategy - The quant system used by the company allows for a broader analysis of approximately 4,500 stocks, compared to traditional analysts who typically cover only 15 to 20 stocks [15][12]. - The quant model incorporates a GARP (Growth at a Reasonable Price) approach, focusing on momentum and positive analyst revisions, which enhances diversification and minimizes risk [13][14]. Market Conditions - Recent market volatility has been influenced by factors such as the government shutdown and uncertainty regarding Federal Reserve interest rate cuts, leading to a rotation towards safer sectors like energy and utilities [21][24][26]. - The CNN fear and greed index indicates a shift from greed to extreme fear in market sentiment, suggesting a cautious outlook among investors [30]. Stock Recommendations Dividend Income Stocks - **Merck (MRK)**: A strong buy with a market cap of $230 billion, a 40% return on equity, and a forward PE of 10.4 times, indicating it is undervalued compared to its sector [43][44][50]. - **Alpine Income Property Trust (PINE)**: A REIT with a market cap of $252 million, offering a forward yield of 6.94% and ranking highly within its sector [51][52]. - **OneMain Holdings (OMF)**: A financial company with a market cap of $6.7 billion, providing a yield of 7.36% and strong growth metrics [64][65]. AI Growth Stocks - **Micron Technology (MU)**: A large-cap company with a market cap of $271 billion, showing significant growth and improved valuation metrics, with a revenue growth rate of 34% [68][70]. - **CommScope Holdings (COMM)**: A smaller company in the communications sector, with a market cap of $3.69 billion, demonstrating strong profitability and growth metrics [73][76]. - **Celestica (CLS)**: A company in the electronic manufacturing services sector, with a market cap showing substantial growth and improved profitability metrics [78][80]. Performance Metrics - The Seeking Alpha quant strong buys have outperformed Wall Street analysts and the S&P 500 over the past five years, with a return of 219% compared to 33% for Wall Street [19]. - The average yield of the recommended dividend stocks is 5.93%, significantly higher than the S&P 500's average yield of 1.1% [81].

2025 年 11 月 23 日 生物医药Ⅱ 新药周观点：小核酸药物治疗乙肝取 得突破性数据 本周新药行情回顾： 2025 年 11 月 17 日-2025 年 11 月 23 日，新药板块涨幅前 5：来凯医 药（+13.34%）、北海康成（+2.67%）、嘉和生物（+2.19%）、永泰生 物 （ +1.94% ）、 友 芝 友 （ +1.14% ）； 跌 幅 前 5 ： 药 明 巨 诺 （ - 15.75%）、艾迪药业（-14.56%）、盟科药业（-14.34%）、宜明昂科 （-13.40%）、凯因科技（-13.04%）。 本周建议关注标的： 考虑板块后续仍有多个催化值得期待，包括学术会议、数据读出、 多个 BD 兑现等，仍建议关注： 1）已获 MNC 认证未来海外放量确定性高的品种：三生制药、联邦制 药、科伦博泰等； 2）存在海外数据催化的品种：贝达药业、和黄医药、映恩生物等； 3）下一个可能海外授权 MNC 的重磅品种：复宏汉霖、石药集团、益 方生物等； 4）新的创新药技术突破领域：小核酸、体内 CAR-T、减脂增肌、自 免 CAR-T/双抗、基因疗法等。 本周新药行业重点分析： 小核酸药物治疗乙肝取得 ...

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Merck, Altria, and Genuine Parts have rewarded shareholders for years and recently announced dividend increases. These companies currently offer dividend yields of up to 7%. Merck Merck & Co. (NYSE:MRK) is a global biopharmaceutical company that discovers, develops, manufactures, and ...

Core Viewpoint - Merck has recommended that its shareholders reject Tutanota's "Mini-Tender" offer, indicating concerns over the offer's terms and potential implications for shareholders [1] Group 1: Company Actions - Merck's board of directors has expressed strong disapproval of Tutanota's offer, emphasizing that it is not in the best interest of shareholders [1] - The company has provided guidance to shareholders on the potential risks associated with accepting the Mini-Tender offer [1] Group 2: Shareholder Impact - The rejection of the Mini-Tender offer is aimed at protecting shareholders from potentially unfavorable terms that may not reflect the true value of their shares [1] - Merck encourages shareholders to remain informed and consider the implications of such offers on their investments [1]

RAHWAY, N.J .--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEXâ,ç¢ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev® (enfortumab vedotin-eifv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who ar. ...

Group 1 - The article emphasizes the opportunity to join a community focused on achieving high dividend yields of 6-7% while maintaining conservative risk-taking strategies [1] - Scott Kaufman, known as Treading Softly, is highlighted as the lead analyst for Dividend Kings, providing insights into high-quality dividend growth and undervalued investment opportunities [1] - The goal of the community is to achieve a robust total return through cash dividends and strong capital gains [1]

Group 1 - The article emphasizes the importance of enabling Javascript and cookies in browsers to avoid access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Group 1 - The author has a background in private credit and commercial real estate (CRE) mezzanine financing, indicating expertise in financial analysis and investment strategies [1] - The author has collaborated with prominent CRE developers, suggesting a strong network and experience in the real estate sector [1] - The author is a fluent Mandarin speaker, which may provide advantages in understanding Asian markets and investment opportunities [1] Group 2 - The article expresses personal opinions and analysis, highlighting the author's independent research approach [2] - The author holds long positions in several pharmaceutical companies, indicating a focus on the healthcare sector for investment [2] - There is no business relationship with the companies mentioned, ensuring an unbiased perspective in the analysis [2]